Global Methotrexate Drug Market TOC
- Market Definition
- Definition
- Market Segmentation
- Product Overview
- Assumptions and Acronyms
- Research Methodology
- Research Process
- Primary Research
- Manufacturers
- Suppliers/Distributors
- End-Users
- Secondary Research
- Market Size Estimation
- Analyst Review
- Executive Summary – Global Methotrexate Drug Market
- Market Dynamics
- Growth Drivers
- Restraints
- Market Trends
- Opportunities
- Regulatory and Standards Landscape
- FDA
- WHO
- Others
- Industry Risk Analysis
- World Economic Outlook: Challenges for Global Recovery and its Impact on Global Methotrexate Drug Market
- Impact of COVID-19 on the Global Methotrexate Drug Market
- Epidemiology Analysis of Cancer and Rheumatoid Arthritis
- End-user analysis
- Industry Supply Chain Analysis
- Competitive Landscape
- Company Market Share Analysis
- Company Profiles
- Pfizer Inc.
- Azurity Pharmaceuticals, Inc.
- Cumberland Pharmaceuticals Inc.
- Teva Pharmaceuticals USA, Inc.
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited,
- Sandoz Inc
- Hikma Pharmaceuticals PLC
- Eisai Co., Ltd.
- Other prominent players
- Global Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- >10 mg, 2023-2036F (USD Million)
- >15 mg/ml, 2023-2036F (USD Million)
- 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- By Disease Type
- Cancer, 2023-2036F (USD Million)
- Breast Cancer, 2023-2036F (USD Million)
- Leukemia, 2023-2036F (USD Million)
- Lung Cancer, 2023-2036F (USD Million)
- Lymphoma, 2023-2036F (USD Million)
- Gestational Trophoblastic Disease, 2023-2036F (USD Million)
- Osteosarcoma, 2023-2036F (USD Million)
- Autoimmune Diseases, 2023-2036F (USD Million)
- Psoriasis, 2023-2036F (USD Million)
- Rheumatoid Arthritis, 2023-2036F (USD Million)
- Crohn's Disease, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- Ectopic Pregnancy, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- Cancer, 2023-2036F (USD Million)
- By Drug Type
- Branded, 2023-2036F (USD Million)
- Generics, 2023-2036F (USD Million)
- By Route Of Administration
- Injectable, 2023-2036F (USD Million)
- Oral, 2023-2036F (USD Million)
- By End User
- Hospitals, 2023-2036F (USD Million)
- Specialty Clinics, 2023-2036F (USD Million)
- Home Healthcare, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- By Region
- North America, 2023-2036F (USD Million)
- Europe, 2023-2036F (USD Million)
- Asia Pacific, 2023-2036F (USD Million))
- Latin America, 2023-2036F (USD Million)
- Middle East & Africa, 2023-2036F (USD Million)
- By Type
- North America Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- >10 mg, 2023-2036F (USD Million)
- >15 mg/ml, 2023-2036F (USD Million)
- 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- By Disease Type
- Cancer, 2023-2036F (USD Million)
- Breast Cancer, 2023-2036F (USD Million)
- Leukemia, 2023-2036F (USD Million)
- Lung Cancer, 2023-2036F (USD Million)
- Lymphoma, 2023-2036F (USD Million)
- Gestational Trophoblastic Disease, 2023-2036F (USD Million)
- Osteosarcoma, 2023-2036F (USD Million)
- Autoimmune Diseases, 2023-2036F (USD Million)
- Psoriasis, 2023-2036F (USD Million)
- Rheumatoid Arthritis, 2023-2036F (USD Million)
- Crohn's Disease, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- Ectopic Pregnancy, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- Cancer, 2023-2036F (USD Million)
- By Drug Type
- Branded, 2023-2036F (USD Million)
- Generics, 2023-2036F (USD Million)
- By Route Of Administration
- Injectable, 2023-2036F (USD Million)
- Oral, 2023-2036F (USD Million)
- By End User
- Hospitals, 2023-2036F (USD Million)
- Specialty Clinics, 2023-2036F (USD Million)
- Home Healthcare, 2023-2036F (USD Million)
- Others, 2023-2036F (USD Million)
- By Country
- United States, 2023-2036F (USD Million)
- Canada, 2023-2036F (USD Million)
- By Type
- Europe Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- By Disease Type
- By Drug Type
- By Route Of Administration
- By End User
- By Country
- United Kingdom, 2023-2036F (USD Million)
- Germany, 2023-2036F (USD Million)
- France, 2023-2036F (USD Million)
- Italy, 2023-2036F (USD Million)
- Spain, 2023-2036F (USD Million)
- Russia, 2023-2036F (USD Million)
- Netherlands, 2023-2036F (USD Million)
- Rest of Europe, 2023-2036F (USD Million)
- Asia Pacific Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- By Disease Type
- By Drug Type
- By Route Of Administration
- By End User
- By Country
- China, 2023-2036F (USD Million)
- India, 2023-2036F (USD Million)
- Japan, 2023-2036F (USD Million)
- South Korea, 2023-2036F (USD Million)
- Singapore, 2023-2036F (USD Million)
- Australia, 2023-2036F (USD Million)
- Rest of Asia Pacific, 2023-2036F (USD Million)
- Latin America Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- By Disease Type
- By Drug Type
- By Route Of Administration
- By End User
- By Country
- Brazil, 2023-2036F (USD Million)
- Mexico, 2023-2036F (USD Million)
- Argentina, 2023-2036F (USD Million)
- Rest of Latin America, 2023-2036F (USD Million)
- Middle East & Africa Methotrexate Drug Market 2023-2036
- Market Overview
- By Value (USD Million)
- By Type
- By Disease Type
- By Drug Type
- By Route Of Administration
- By End User
- By Country
- Israel, 2023-2036F (USD Million)
- GCC, 2023-2036F (USD Million)
- South Africa, 2023-2036F (USD Million)
- Rest of Middle East & Africa, 2023-2036F (USD Million)
Global Methotrexate Drugs Market Trends, Forecast Report 2025-2037
Methotrexate Drugs Market size is projected to increase from USD 584.09 million to USD 846.99 million, registering a CAGR of over 2.9% during the forecast period, from 2025 to 2037. In the year 2025, the industry size of methotrexate drugs is estimated at USD 597.64 million.
The demand for methotrexate drugs is owing to increasing use of the drugs for various inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, and lupus. About 60% of people with rheumatoid arthritis are presently taking methotrexate, which is the recommended first-line treatment for rheumatoid arthritis, according to the American College of Rheumatology. Moreover, rising prevalence of autoimmune diseases is driving the market growth. As manufacturers are focusing on innovating new drugs in order to reduce the challenges faced by patients.
Methotrexate Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Cancer – Methotrexate is commonly used in chemotherapy. It's a treatment for several different types of cancer. Although Methotrexate is not a first-line drug against breast cancer, it might be valuable in fighting the disease due to which the methotrexate drugs market rapidly expanding. According to the World Health Organization (WHO), cancer was the top cause of death globally in 2020, accounting for close to more than 10 million deaths, or about one in every six. The most prevalent types are breast, lung, colon, rectum, and prostate cancers. The second most significant cause of death for women after lung cancer is breast cancer, the most recurring invasive cancer in females.
- Need for Cost-Effective Medicines- Methotrexate has been on the market for several decades, making it a relatively affordable option compared to newer, more expensive drugs. Its cost-effectiveness has made it a preferred choice for healthcare providers and patients.
- Increasing Number of Methotrexate Drugs Approvals – The rising number of drug approval is expected to increase the methotrexate drugs market growth. For example, U.S. specialty pharmaceutical company Cumberland Pharmaceuticals Inc. announced the launch of her RediTrex injection in November 2020. RediTrex is a new prefilled syringe specifically designed for precise dosing for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis and is easy to use. Besides, in July 2022, The US Food and Drug Administration approved use of methotrexate to lower serum uric acid levels (sUA) in patients with chronic gout.
Challenges
- Obstruction of Approval of Methotrexate Injection - Due to its drawbacks such as the lengthy development process and stringent regulations, the methotrexate drugs market is facing certain limitations across the world. As methotrexate injection may cause a serious, life-threatening reaction that may occur while or shortly after one receives this medication. Moreover, for individualized prediction of response to methotrexate treatment in patients with RA, clinically useful tools are lacking, which is also a key threat to the market.
- Lack of Awareness and High Cost of Rheumatoid Arthritis Drugs
- Side Effects Caused by the Drug
Methotrexate Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
2.9% |
|
Base Year Market Size (2024) |
USD 584.09 million |
|
Forecast Year Market Size (2037) |
USD 846.99 million |
|
Regional Scope |
|
Methotrexate Drugs Segmentation
End-user (Hospitals, Specialty Clinics, Home Healthcare)
The hospital segment is set to account for largest market share by the end of 2037. This can be attributed to large number of patients who require sophisticated wound care, and/or are admitted to hospitals, either for surgery or the treatment of chronic illnesses such as diabetes or pressure ulcers. Hospitals also have the equipment and people needed to offer sophisticated wound care, such as growth factor treatments and negative pressure wound therapy (NPWT).
Application (Chronic, Acute Wounds)
The chronic wounds segment is anticipated to hold largest market size by 2037, on account of increasing prevalence of chronic wounds as in the case of diabetes, pressure ulcers, and other diseases. The incidence of chronic ulcers in 2018 was over 2 people per 1000 population and for chronic leg ulcers, it ranges at 1 person per 1000 people.
Our in-depth analysis of the global methotrexate drugs market includes the following segments:
|
Dosage Form |
|
|
Drug Type |
|
|
Disease Type |
|
|
Route of Administration |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMethotrexate Drugs Industry- Regional Synopsis
The North America advanced wound care market is predicted to account for majority share by the end of 2037. A strong healthcare infrastructure and an increase in surgical operations will impel the market growth in the region. Thus, the adoption of advanced wound care treatments to stop surgical site infections is growing. Moreover, the market expansion is driven by an increase in the frequency of incidents such as traffic accidents, burns, and trauma events worldwide.
Additionally, rising disposable income to spend on facial corrections and growing awareness among people regarding advanced wound care management devices will propel the market revenue. In 2019, about a 2% increase is observed in per capita disposable income in the North America region, as per the estimations. Furthermore, the expansion of the global advanced wound care market in this region is being aided by the rising number of acquisitions made by renowned businesses based in North America. The growth is also supported by demographic shifts, rising patient awareness, and a highly developed market for wound care products.
Companies Dominating the Methotrexate Drugs Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Azurity Pharmaceuticals, Inc.
- Cumberland Pharmaceuticals Inc.
- Teva Pharmaceuticals USA, Inc.
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited,
- Sandoz Inc
- Hikma Pharmaceuticals PLC
- Eisai Co., Ltd.
In the News
- Eisai Co., Ltd and nippon medac Co., Ltd. announced a manufacturing and marketing approval of Metoject Subcutaneous Injection (Methotrexate) from the Japanese Ministry of Health, Labour and Welfare for the treatment of rheumatoid arthritis.
- Cumberland Pharmaceuticals Inc. announced the launch of RediTrex (methotrexate) injection which is designed for dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.
Author Credits: Radhika Pawar
- Report ID: 2738
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT
